Another portfolio biotech gem just delivered a quarterly update showing the best-ever results achieved so far.

Well-capitalised balance sheet, strong synergies across product lines, fast-growing international penetration.

Over the last few quarters, institutions have been accumulating heavily; no doubt, we will soon see the price impact.

Waiting. In a good company with paid subscribers who followed the idea and joined the show.